CAJ | 학술논문

目的评估表浅性膀胱癌经尿道膀胱肿瘤电切术(TU RBT)后行即刻膀胱灌吡柔比星的临床效果.方法选取102例表浅性膀胱癌患者,随机分为即刻膀胱灌注组(A组,n =57)和常规膀胱灌注组(B组,n=45),A组于术后6h内应用吡柔比星30 mg膀胱灌注,两组术后1周均行吡柔比星常规灌注化疗,随访比较两组患者术后肿瘤复发及发生并发症情况.结果术后A组复发8例(14.03％),复发时间平均为术后15个月；B组复发15例(33.33％),复发时间平均为术后10个月.两组比较,A组复发率低于B组(P＜0.05),复发时间推迟(P＜0.05).膀胱灌注后共27例患者出现膀胱炎、血尿等并发症.两组间比较差异无统计学意义(P＞0.05).结论表浅性膀胱癌经尿道膀胱肿瘤电切术后行吡柔比星即刻膀胱灌注治疗安全、有效,能明显降低肿瘤复发率,延迟复发时间,不增加并发症发生率.
목적 평고표천성방광암경뇨도방광종류전절술(TU RBT)후행즉각방광관필유비성적림상효과.방법 선취102례표천성방광암환자,수궤분위즉각방광관주조(A조,n =57)화상규방광관주조(B조,n=45),A조우술후6h내응용필유비성30 mg방광관주,량조술후1주균행필유비성상규관주화료,수방비교량조환자술후종류복발급발생병발증정황.결과 술후A조복발8례(14.03％),복발시간평균위술후15개월；B조복발15례(33.33％),복발시간평균위술후10개월.량조비교,A조복발솔저우B조(P＜0.05),복발시간추지(P＜0.05).방광관주후공27례환자출현방광염、혈뇨등병발증.량조간비교차이무통계학의의(P＞0.05).결론 표천성방광암경뇨도방광종류전절술후행필유비성즉각방광관주치료안전、유효,능명현강저종류복발솔,연지복발시간,불증가병발증발생솔.
Objective To evaluate the clinical effect of instantly intravesical instillation of pirarubicin for preventing recurrence of superficial bladder cancer after transurethral bladder tumor resection.Methods One hundred and two cases of superficial bladder cancer were randomly divided into instantly instillation group (group A,n =57) and routine instillation group (group B,n =45).Group A accepted intravesical instillation of pirarubicin 30 mg within 6 h after transurethral bladder tumor resection.Then two groups started routine treatment of pirarubicin after 1 week of operation.The tumor recurrence rates and the complications associated with therapy were observed between the two groups.Results After operation,the tumor recurrence rates of group A (8 cases) and g,roup B (15 cases) were 14.03％ and 33.33％,the average recurrent time of group A and group B were 15 months and 10 months.There were significant differences between the two groups in recurrence rates and average recurrent time (P ＜ 0.05).After intravesical instillation,27 cases of patients were complicated by cystitis or hematuria.There were no significant differences between the two groups(P ＞ 0.05).Conclusions Instantly intravesical instillation of pirarubicin is a effective and safe method for superficial bladder cancer after TURBT.It can reduce the tumor recurrence rate and prolong the average recurrent time without increasing the incidence of complications.